- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00538811
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
October 26, 2010 updated by: Aga Khan University
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin
When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha.
Enhancement of immune responses, especially those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C. The aim of the present study is to evaluate the efficacy and safety of a triple regimen, a combination treatment with Interferon gamma, Interferon alfa-2b plus Ribavirin in patients who have not previously responded to interferon alpha in combination of ribavirin.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Karachi, Pakistan, 74800
- The Aga Khan University Hospital
-
Karachi, Pakistan, 74800
- Medicare Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Non-responders and relapsers to previous interferon and ribavirin therapy given for six months
- HCV genotype 3
- Compensated liver disease
- Hb ≥10 g/dl (females),≥11 g/dl (males)
- Platelets count ≥ 100,000 / cubic mm
- Neutrophils count ≥1,500/cubic mm
- ≥18 years to ≤ 70 years.
- At least one abnormal ALT value in the last year.
- TSH level within normal limits.
- Non pregnant adult females.
- Absence of drug or alcohol abuse.
- Informed consent given by the patient
Exclusion Criteria:
- Patient younger than 18 yrs and older than 70 yrs.
- Hepatitis B or HIV co-infection.
- Severe renal dysfunction or creatinine clearance less than 50 ml/min
- Pregnant women or breast feeding women.
- Suspected hypersensitivity to Interferon alpha, gamma or ribavirin.
- Decompensated liver cirrhosis.
- History or any other evidence of other causes of CLD other than hepatitis C infection ( like hemochromatosis,, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure, Wilson's disease,Drug induced liver disease)
- Active malignant disease.
- Any known pre-existing medical condition that could interfere with subject's participation or completion of study such as psychiatric condition, seizures disorder requiring medications, co existing heart diseases, lung diseases, poorly controlled diabetes, auto immune diseases, gout)
- History of interferon and/or ribavirin intolerance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Interferon alpha, ribavirin, interferon gamma
|
|
Active Comparator: 2
Interferon alpha, ribavirin, amantadine
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Zaigham Abbas, FCPS, FACG, The Aga Khan University Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
October 2, 2007
First Submitted That Met QC Criteria
October 2, 2007
First Posted (Estimate)
October 3, 2007
Study Record Updates
Last Update Posted (Estimate)
October 27, 2010
Last Update Submitted That Met QC Criteria
October 26, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Dopamine Agents
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Interferons
- Interferon-alpha
- Ribavirin
- Interferon alpha-2
- Interferon-gamma
- Amantadine
Other Study ID Numbers
- 648-Med
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
Clinical Trials on interferon alpha-2b, ribavirin, interferon-gamma,
-
National Taiwan University HospitalSchering-PloughCompletedChronic Hepatitis B
-
Junqi NiuChinese Academy of SciencesUnknownLiver Diseases | Hepatitis C, Chronic | Interferon DeficiencyChina
-
The First Hospital of Jilin UniversityChinese Academy of SciencesUnknown
-
InterMuneCompletedChronic Hepatitis CUnited States
-
Brooke Army Medical CenterT.R.U.E. Research FoundationCompleted
-
HepNet Study House, German LiverfoundationHannover Medical SchoolTerminatedHepatitis C, ChronicGermany
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Hepatitis CPuerto Rico
-
French National Agency for Research on AIDS and...Hoffmann-La Roche; InterMuneCompletedHepatitis C, ChronicFrance
-
Ullevaal University HospitalSchering-PloughCompletedHepatitis C Virus InfectionNorway
-
MTI Medical Private Limited, PakistanUnknown